Novartis

MSN labs seeks pause of order blocking ’Novadoz’ during appeal Bloomberg Law20:44
Pharma company to lay off 427 at its N.J. headquarters NJ.com - The Jersey Journal20:44
Novartis urges court to make FDA block Entresto generic Law36000:56
Amid Trump's push to abolish Dei, Roche and Novartis adjust hiring initiatives: reports FiercePharma18:36
Novartis new data from single-dose gene therapy shows meaningful efficacy, safety in patients with spinal muscular… Benzinga17:22
Marinakis vs. Tsoukalas: Pasok is essentially whitewashing the manipulations of the Novartis conspiracy Proto Thema News16:58
Novartis wins partial ban against MSN's heart drug generic Law36002:40

Latest News

In the last 6 hours

Novartis Flags Entresto Copy Risk as MSN Seeks to Delist Patent Bloomberg Law18:35

In the last 8 hours

Nephrologists Embrace Earlier, More Aggressive IgAN Treatment as Branded Therapies from Calliditas, Travere, and… GlobeNewswire (Press Release)17:38

Earlier today

Roche’s Ocrevus, Novartis’ Kesimpta set to lead CNS market to strongest growth in over a… FiercePharma15:06

Yesterday

MSN Labs Seeks Pause of Order Blocking ’Novadoz’ During Appeal Bloomberg Law20:44 25-Mar-25

FDA Approves Novartis Oral Treatment for Adults with C3 Glomerulopathy PharmTech.com19:02 25-Mar-25

Smart Pills Market Forecast Report and Company Analysis 2025-2033 Featuring Check-Cap, General… Business Wire (Press Release)17:49 25-Mar-25

Novartis’ Fabhalta granted FDA approval to treat ultra-rare kidney disease C3G PMLiVE12:30 25-Mar-25

India Urinary Tract Infection (UTI) Treatment Market Research 2025-2033 Featuring Analysis of Key Players -… GlobeNewswire (Press Release)09:45 25-Mar-25

Novartis to present new data at Aan, including seven-year disability outcomes and safety analysis of Kesimpta® in… GlobeNewswire (Press Release)06:22 25-Mar-25

Chinese VP meets John Swire & Sons Limited CEO, Novartis CEO Xinhua Agency06:13 25-Mar-25

Chinese vice president meets Swire Pacific Ltd. chairman, Novartis CEO CGTN02:24 25-Mar-25

In the last 7 days

With Fabhalta’s C3G Approval, Now Novartis Has To Find The Patients Scrip Pharma Intelligence21:43 24-Mar-25

Chinese VP meets Swire Pacific Limited chairman, Novartis CEO Xinhua Agency13:46 24-Mar-25

India Vision Care Market Size and Share Analysis 2025-2033 Featuring Bausch & Lomb, Alcon Labs, Hoya Lens, Johnson &… GlobeNewswire (Press Release)11:23 24-Mar-25

Tempero Bio, led by ex-Novartis execs, gets $70M to reduce substance use disorders ENDPOINTS11:03 24-Mar-25

Novartis Urges Court To Make FDA Block Entresto Generic Law36000:56 22-Mar-25

FDA Approves Novartis Drug for Rare Kidney Disease Treatment Zacks17:33 21-Mar-25

FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease Benzinga15:58 21-Mar-25

Novartis links music and science in corporate campaign tied to Eurovision sponsorship FiercePharma15:54 21-Mar-25

FDA approves Novartis’ Fabhalta in C3 glomerulopathy ENDPOINTS15:47 21-Mar-25

Novartis snags FDA nod for Fabhalta in another kidney disease but leaves room for rival Apellis FiercePharma14:52 21-Mar-25

Fabhalta is first FDA-approved therapy for rare disease C3G pharmaphorum12:30 21-Mar-25

NVS Crosses Above Average Analyst Target Nasdaq11:08 21-Mar-25

FDA approves Novartis’ Fabhalta for C3 glomerulopathy treatment Pharmaceutical Business Review11:07 21-Mar-25

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3… GlobeNewswire (Press Release)23:13 20-Mar-25

Abbott Settles Suit on HIV-Testing Patent With Novartis, Grifols Bloomberg Law21:01 20-Mar-25

Novartis Reports Updated Positive Data From Phase III SMA Program Zacks14:04 20-Mar-25

Novartis shares positive phase 3 results for spinal muscular atrophy gene therapy PMLiVE12:24 20-Mar-25

Novartis reports Phase III efficacy and safety outcomes of SMA treatment Clinical Trials Arena11:45 20-Mar-25

Novartis touts Zolgensma data in older children ENDPOINTS19:53 19-Mar-25

Amid Trump's push to abolish DEI, Roche and Novartis adjust hiring initiatives: reports FiercePharma18:36 19-Mar-25

Novartis New Data From Single-Dose Gene Therapy Shows Meaningful Efficacy, Safety In Patients With Spinal Muscular… Benzinga17:22 19-Mar-25

Marinakis vs. Tsoukalas: PASOK is essentially whitewashing the manipulations of the Novartis conspiracy Proto Thema News16:58 19-Mar-25

Urinary Tract Infection Treatment Market Forecast Report and Company Analysis 2025-2033 Featuring AstraZeneca, Bayer,… GlobeNewswire (Press Release)16:18 19-Mar-25

Novartis scraps use of diverse panels for hires in US KELO TV14:07 19-Mar-25

Novartis details intrathecal Zolgensma data in bid to reach more SMA patients with gene therapy FiercePharma13:12 19-Mar-25

New Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal… PR Newswire (Press Release)13:03 19-Mar-25

Novartis sheds staff as Entresto patent expiry looms pharmaphorum09:31 19-Mar-25

HHS Seeks Early Win Over Lilly, Novartis, BMS In Rebate Row Law36002:04 19-Mar-25

In the last month

Pharma company to lay off 427 at its N.J. headquarters NJ.com - The Jersey Journal20:44 18-Mar-25

Novartis Gets Early Edge in Clash Over ’Novadoz’ Entresto Copy Bloomberg Law20:00 18-Mar-25

400+ Workers To Be Laid Off At NJ Pharmaceutical Company Patch18:54 18-Mar-25

Novartis plots 427 layoffs in New Jersey as looming Entresto patent cliff sparks marketing… FiercePharma14:25 18-Mar-25

Novartis to cut 400+ staffers in revamp of cardiovascular commercialization model ENDPOINTS12:02 18-Mar-25

Novartis Wins Partial Ban Against MSN's Heart Drug Generic Law36002:40 18-Mar-25

Novartis CEO says it is watching US reciprocal tariff policy 'very carefully' Yahoo! US06:06 17-Mar-25

Circulating DNA RNA Patent Landscape Report and Forecast 2024-2032: Nantomics, Genentech, and Novartis are Pivotal in… GlobeNewswire (Press Release)16:31 14-Mar-25

NFL unlocks pharma category with Novartis Sport Business11:44 14-Mar-25

Liver Disease Therapeutic Market Forecast Report and Company Analysis 2025-2033 Featuring Abbott, Astellas, BMS, Gilead … GlobeNewswire (Press Release)11:19 14-Mar-25

For years, a K-pop singer’s pain went unnamed. At a Novartis screening, he shared why. Korea Biomedical Review04:32 14-Mar-25

NFL drafts Novartis as league’s first corporate pharma partner FiercePharma15:45 13-Mar-25

Novartis named first-ever corporate pharmaceutical partner of the National Football League PR Newswire (Press Release)15:14 13-Mar-25

NFL signs Novartis as first pharmaceutical partner-source KELO TV12:34 13-Mar-25

Novartis Pharmaceuticals and Folia Health Partner on Innovative App-Based Study to Assess Real-World Experience of IgA… GlobeNewswire (Press Release)12:06 13-Mar-25

Law360 Cheat Sheet: Novartis' Fight Over Generic Entresto Law36001:16 13-Mar-25

Why João Camacho of Saatchi Wellness Believes Healthcare Is the Best Canvas for Creativity Muse by Clio09:47 12-Mar-25

Purespring Therapeutics appoints Haseeb Ahmad as Chief Executive Officer GlobeNewswire (Press Release)07:01 12-Mar-25

A Later-Discovered Improvement to an Invention Cannot Be Used To Reach Back and Invalidate an Earlier-Filed Patent JD Supra16:31 11-Mar-25

mRNA Cancer Therapeutics Patent Landscape Report and Forecast 2024-2032 Featuring Pfizer, Moderna, and Novartis with… GlobeNewswire (Press Release)15:24 11-Mar-25

Novartis gains rights to Kyorin’s chronic spontaneous urticaria candidate in deal worth $830m PMLiVE12:29 11-Mar-25

Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights GlobeNewswire (Press Release)11:10 11-Mar-25

Novartis sees radioactive cancer drugs becoming $10bn business: CEO Nikkei Asian Review19:44 10-Mar-25

GSK, Novartis, Lilly among Big Pharmas celebrating International Women’s Day 2025 FiercePharma15:32 10-Mar-25

Novartis reaffirms commitment towards gender equity The Sun Daily11:59 9-Mar-25

Zollinger Ellison Syndrome Market Research 2025: Novartis, GSK Plc, Bayer, Pfizer., and Bristol Myers Squibb Leading… GlobeNewswire (Press Release)16:42 7-Mar-25

CytomX, Amgen pass on T cell engager; Molecular Partners ends work with Novartis ENDPOINTS15:10 7-Mar-25

Aktionäre von Novartis heissen an der Generalversammlung 2025 alle Anträge des Verwaltungsrats gut Novartis (Press Release)14:25 7-Mar-25

Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2025 Annual General Meeting GlobeNewswire (Press Release)14:20 7-Mar-25

Neurology Market Research Overview 2025, Profiles of Major Players - F. Hoffmann-La Roche,… Business Wire (Press Release)17:25 6-Mar-25

CDMO Partnership Reimagined – Novartis Contract Manufacturing PharmTech.com16:19 6-Mar-25

ITM reports more Phase 3 radiopharma data in challenge to Novartis’ Lutathera ENDPOINTS09:30 6-Mar-25

Novartis to mass produce next-generation cancer drugs in Japan Nikkei Asian Review16:32 5-Mar-25

Novartis Joins MRGPRX2 Race Through $800m+ Kyorin Deal Scrip Pharma Intelligence07:08 5-Mar-25

Novartis adds Kyorin’s preclinical MRGPRX2 antagonist in $777M deal BioWorld20:17 4-Mar-25

Novartis Treatment for C3G Gets Positive Opinion from EMA PharmTech.com15:08 4-Mar-25

Novartis (VTX:NOVN) Has Announced That It Will Be Increasing Its Dividend To $3.50 Simply Wall St10:09 4-Mar-25

Novartis hands over $55M upfront to license preclinical hives prospect from Japan's Kyorin FierceBiotech22:15 3-Mar-25

Novartis licenses Kyorin’s preclinical chronic hives candidate for $55M upfront ENDPOINTS16:05 3-Mar-25

Novartis Gets CHMP Opinion for Label Expansion of Fabhalta Zacks14:06 3-Mar-25

Rare diseases: Novartis’ Fabhalta recommended by CHMP for C3 glomerulopathy PMLiVE12:31 3-Mar-25

EMA’s CHMP recommends marketing authorisation for Novartis’ Fabhalta Pharmaceutical Business Review12:28 3-Mar-25

The Oscars Are the Super Bowl For Brands Targeting Women Adweek11:29 3-Mar-25

KYORIN and Novartis Forge Global License Agreement for KRP-M223 TipRanks07:48 3-Mar-25

Big Pharmas ‘line up’ for BasgenBio’s AI drug target tech as it nears $70 mil. licensing deal: CEO Korea Biomedical Review00:57 3-Mar-25

IPBC Korea; VideoLabs interview; Philips DVD SEP victory; Novartis IP head on Trump; landmark UK Ericsson ruling; plus… IAM12:06 2-Mar-25

HC adjourns hearing on plea for probing Novartis share transfer till March 6 Bangladesh Sangbad Sangstha09:11 2-Mar-25

CHMP recommends Regeneron, Novartis drugs that still await FDA approval ENDPOINTS17:55 28-Feb-25

Novartis data presentations at Aaaai and Aad underscore commitment to advancing treatment of hidradenitis suppurativa… GlobeNewswire (Press Release)14:04 28-Feb-25

Novartis oral Fabhalta® (iptacopan) receives positive Chmp opinion for the treatment of adults living with C3… GlobeNewswire (Press Release)12:43 28-Feb-25

Why Novartis Remains A 'Buy' After Beating Expectations Again Seeking Alpha20:59 27-Feb-25

Novartis Pharmaceuticals Corp. v. Becerra Public Citizen20:39 27-Feb-25

MSN Says Novartis Is Using Bad Patent to Stall Entresto Copies Bloomberg Law20:20 27-Feb-25

Seizures Pipeline Insight Analysis Report, Competitive Analysis of Eisai, Novartis, Johnson & Johnson, and Neurelis GlobeNewswire (Press Release)15:17 27-Feb-25

Novartis IP policy head's hopes for Trump 2.0 IAM15:10 27-Feb-25

Novartis Korea expands indication for chronic myeloid leukemia treatment Scemblix Korea Biomedical Review06:50 27-Feb-25

The Polycythemia Vera Market Landscape Heats Up Amid Rising Competition Among Pharma Companies… PR Newswire (Press Release)22:37 26-Feb-25

Block of €3.4bn in Ferrari tops €2.8bn Novartis trade Global Capital19:06 26-Feb-25

Sandoz family's Novartis sale totals US$2.91bn International Financing Review18:57 26-Feb-25

Sandoz Family to Sell $2.9 Billion Stake in Novartis Mint14:21 26-Feb-25

Sandoz family to get $2.9 billion from offloading part of its Novartis stake Yahoo! US10:39 26-Feb-25

Syngenta acquires genetic repository from Novartis to boost biologic crop protection KELO TV10:24 26-Feb-25

Syngenta strengthens global leadership in agricultural biologicals Business Wire (Press Release)08:02 26-Feb-25

Sandoz family foundation offers $3 billion worth of Novartis shares KELO TV20:51 25-Feb-25

Novartis’ Bid to Block Missouri’s Drug Discount Law Rejected Bloomberg Law18:59 25-Feb-25

view more headlines

26 Mar 18:35

About our Novartis news

Latest news for Novartis, a global healthcare company based in Switzerland specialising in pharmaceuticals, including updates on company and product news.

Novartis

Latest News

About our Novartis news

Pharmaceuticals Top Stories

UK Top Stories

World Top Stories